Chapter 2

Salmonella Induced IL-23 and IL-1β Allow for IL-12 Production by Monocytes and Mφ1 through Induction of IFN-γ in CD56⁺ NK/NK-like T cells

Diederik van de Wetering, Roelof A. de Paus, Jaap T. van Dissel, Esther van de Vosse

PLoS One 2009 Dec 21;4(12):e8396.
Abstract

Background The type-1 cytokine pathway plays a pivotal role in immunity against intracellular bacterial pathogens such as *Salmonellae* and *Mycobacteria*. Bacterial stimulation of pattern recognition receptors on monocytes, macrophages and dendritic cells initiates this pathway, and results in the production of cytokines that activate lymphocytes to produce interferon (IFN)-γ. Interleukin (IL)-12 and IL-23 are thought to be the key cytokines required for initiating a type-1 cytokine immune response to *Mycobacteria* and *Salmonellae*. The relative contribution of IL-23 and IL-12 to this process is uncertain.

Methodology/Principal Findings We show that various TLR agonists induce the production of IL-23 but not IL-12 in freshly isolated human monocytes and cultured human macrophages. In addition, type 1 pro-inflammatory macrophages (Mφ1) differentiated in the presence of GM-CSF and infected with live *Salmonella* produce IL-23, IL-1β and IL-18, but not IL-12. Supernatants of *Salmonella*-infected Mφ1 contained more IL-18 and IL-1β as compared with supernatants of Mφ1 stimulated with isolated TLR agonists, and induced IFN-γ production in human CD56+ cells in an IL-23 and IL-1β-dependent but IL-12-independent manner. In addition, IL-23 together with IL-18 or IL-1β led to the production of GM-CSF in CD56+ cells. Both IFN-γ and GM-CSF enhanced IL-23 production by monocytes in response to TLR agonists, as well as induced IL-12 production.

Conclusions/Significance The findings implicate a positive feedback loop in which IL-23 can enhance its release via induction of IFN-γ and GM-CSF. The IL-23 induced cytokines allow for the subsequent production of IL-12 and amplify the IFN-γ production in the type-1 cytokine pathway.
Introduction

Immunity against intracellular bacterial pathogens such as *Salmonellae* and *Mycobacteria* depends on the type-1 cytokine pathway (1). This pathway is initiated by bacterial stimulation of pattern recognition receptors on monocytes and macrophages, resulting in the production of cytokines that activate lymphocytes and induce IFN-\(\gamma\) production. The IFN-\(\gamma\) in turn activates monocytes and macrophages, to enhance bactericidal effector mechanisms and to further pro-inflammatory cytokine production. Thus, the type-1 cytokine pathway critically depends on the cross-talk between monocytes/macrophages and lymphocytes. Abdi *et al.* state that IL-12p70 cannot be the primary trigger that initiates Th1 T-cell responses, as it is not produced in response to bacterial stimulation when costimulation in the form of activated T cells or IFN-\(\gamma\) are absent (2). In addition, in whole blood assays with blood obtained from patients with complete IFN-\(\gamma\)R deficiency, no IL-12p70 production can be detected in response to *M. bovis* BCG infection *in vitro* (3). How the type-1 pathway is initiated, therefore, has remained uncertain.

Interleukin-23 (IL-23) is a cytokine which is produced early in the immune response (4). Monocytes as well as type 1 macrophages (M\(\Phi\)1) produce IL-23 in response to the binding of pathogens and pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS), to Toll-like receptors (TLRs) (5,6). In contrast to IL-23, for the production of IL-12 in response to PAMPs an additional stimulus such as IFN-\(\gamma\) is required (5). IL-23 is known to induce IFN-\(\gamma\) production in naïve T cells, in memory T cells (7) and in NK-like T cells (8), thereby potentially providing the necessary, additional stimulus to induce IL-12 production. Next, IL-12 and IL-18 enhance IFN-\(\gamma\) production in NK, NK-like T cells and Th1 cells by binding to their respective receptors (9). Though IFN-\(\gamma\) is not required for the induction of IL-23, the precise role of IFN-\(\gamma\) in the regulation of IL-23 is not well established.

Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is a cytokine produced by NK cells and T cells in response to a variety of stimuli, for instance IL-15 and IL-18 (10). GM-CSF activates monocytes and enhances their bactericidal activity (11-13). Moreover, monocytes pre-stimulated with GM-CSF secrete increased quantities of tumor necrosis factor (TNF) and IL-1\(\beta\) when stimulated with LPS (14,15). Furthermore, GM-CSF induces differentiation of human monocytes into M\(\Phi\)1, a macrophage type that is capable of producing IL-23 (5).

In this study we addressed the roles of the cytokines IL-23, IL-1\(\beta\), IL-18, GM-CSF and IFN-\(\gamma\) in the crosstalk between NK/NK-like T cells and monocytes/macrophages in the early activation of the type-1 cytokine pathway. To this end we determined which TLR agonists induce IL-23 production in human monocytes and macrophages and assessed the roles of GM-CSF and IFN-\(\gamma\) in the regulation of IL-23 production by human monocytes in response to TLR agonists. Furthermore, we explored the role of *Salmonella*-induced IL-23, IL-1\(\beta\) and IL-18 in the induction of
IFN-γ in primary human NK/NK-like T cells, and tested the capacities of IL-23, IL-1β and IL-18 to induce GM-CSF and IFN-γ in human NK and NK-like T cells.

**Materials and Methods**

**Cells and culture conditions**

Human CD14⁺ cells and CD56⁺ cells were isolated from buffy coats from healthy donors (Sanquin) by Ficoll-Amidotrizoate density gradient centrifugation and subsequent selection with anti-CD14 MACS beads or anti-CD56 MACS beads (Miltenyi Biotech). CD14⁺ cells were cultured in RPMI-1630 medium, supplemented with 20 mM GlutaMAX (Gibco/Invitrogen), 10% FCS, 100 U/ml Penicillin, 100 µg/ml Streptomycin (Gibco/Invitrogen). CD56⁺ cells were cultured in Iscove's modified Dulbecco's medium (IMDM, Bio-Whittaker) supplemented with 20 mM GlutaMAX, 10% FCS, 100 U/ml Penicillin, 100 µg/ml Streptomycin. To generate MΦ1, CD14⁺ cells were cultured for 6 days in RPMI 1640 with 10% FCS and 5 ng/ml GM-CSF (Biosource) in 75 cm² or 175 cm² cell culture flasks (Greiner Bio-One).

**Cytokine induction and measurement**

To determine cytokine production by monocytes, CD14⁺ beads isolated cells were seeded in a 96-well plate at 1·10⁵ cells per well and cultured for 24 h in the presence or absence of the following TLR agonists: 100 ng/ml *S. minnesota* LPS (Sigma), 200 ng/ml recombinant flagellin (tlrl-flic, InvivoGen), 1 µg/ml Pam3CSK4 (tlrl-pms, InvivoGen), 100 µg/ml Zymosan A (Sigma), 1 µg/ml CL075 (tlrl-c75, InvivoGen) or 1 µg/ml CL087 (tlrl-c87, InvivoGen) in a final volume of 200 µl. Supernatants were taken and IL-23 (eBioscience), IL-1β (Biosource) IL-18 (MBL) and IL-12p70 (Sanquin) concentrations were determined by ELISA. For experiments with MΦ1, cells were harvested with trypsin-EDTA, washed with PBS and seeded at 3.3·10⁵ per well in 24-well or 1·10⁶ in 12-well culture plates (Corning Life Sciences) and allowed to adhere. Subsequently MΦ1 were stimulated with TLR agonists, infected with group B *Salmonella* at a 10:1 multiplicity of infection as described below, or left unstimulated. Twenty-four hours after stimulation, supernatants were collected and cytokine production was determined by ELISA. To test the effect of GM-CSF and IFN-γ pre-stimulation, 1·10⁵ CD14⁺ monocytes were cultured for 16 hours with 50-5000 pg/ml GM-CSF, 50-5000 pg/ml IFN-γ (Biosource) or left unstimulated. Subsequently cells were stimulated with 100 ng/ml LPS plus 1 µg/ml CL075 for 24 hours, or left unstimulated. After stimulation cell free supernatants were collected and IL-23 production was determined by ELISA (eBioscience).
**Supernatant transfer experiments**

To generate supernatants from *Salmonella* stimulated Mφ1, 1·10^6 cells were seeded in a 12-well plate and infected with group B *Salmonella* at a 10:1 multiplicity of infection. To promote the uptake of bacteria, the bacteria were spun onto the macrophages by centrifugation at 300 × g for 5 min and the cells were allowed to internalize the bacteria for 30 min at 37°C, 5% CO₂. Cells were washed 3 times with PBS after which medium containing 50 μg/ml gentamicin (Sigma) was added to kill extracellular Salmonellae. After 30 minutes, medium was replaced with 2 ml fresh medium containing 10 μg/ml gentamicin. Twenty-four hours after infection, cell free supernatants were collected and used to stimulate anti-CD56 beads isolated cells. Overnight rested CD56⁺ cells were seeded 1·10^5 cells per well in a 96-well plate and stimulated for 48 hr with 100 μl of conditioned Mφ1 medium, with or without 100 ng/ml IL-18 (MBL), in a final volume of 200 μl. After 48 hours of culture, cell free supernatants were collected and used to stimulate IFN-γ production was measured by cytokine specific ELISA (Biosource). For cytokine neutralization assays, macrophage supernatants were pre-incubated with 10 μg/ml anti-IL-12p40 (C8.6, eBiosciences) or 10 μg/ml anti-IL-18 (MBL) or 5 μg/ml anti IL-1β (BD Biosciences) for 30 minutes at 37°C.

To generate supernatants of CD56⁺ cells, 1·10^6 cells were stimulated with 10 ng/ml IL-23 plus 10 ng/ml IL-1β, or left unstimulated, for 24 hours. Cell free supernatants were collected and used to stimulate CD14⁺ monocytes. CD14⁺ cells were seeded 1·10^5 cells per well in a 96-well plate and stimulated for 24 hr with 100 ng/ml LPS, in combination with 100 μl supernatant of CD56⁺ cells, 2.5 ng/ml IFN-γ (Biosource) or medium in a final volume of 200 μl. To neutralize IFN-γ, supernatants from stimulated CD56⁺ cells were pre-incubated with 2 μg/ml anti-IFN-γ (Genzyme) for 30 minutes at 37°C. Supernatants were collected and IL-12p70 was measured by cytokine specific ELISA (BD Bioscience).

**IFN-γ and GM-CSF production**

To determine GM-CSF and IFN-γ production in NK and NK-like T cells, overnight-rested CD56⁺ beads-isolated cells were seeded 1·10^5 cells per well in a 96-well plate and stimulated for 24 hr with various concentrations of IL-23, alone or in combination with various concentrations of IL-18 (MBL) or IL-1β (Biosource) in a final volume of 200 μl. Concentrations of IFN-γ and GM-CSF in the cell free supernatants were determined by cytokine-specific ELISA (Biosource).

For intracellular staining of IFN-γ, CD56⁺ beads-isolated cells were seeded 10^5 cells/well in 96-well plates and stimulated with IL-23 (R&D Systems), IL-18 (MBL), IL-1β (Biosource) or a combination of these cytokines for 48 hours. The last 5 hours of stimulation BD GolgiPlug (BD PharMingen) was added (final concentration 1:1000). Cells were fixed in 4% paraformaldehyde (Sigma) and permeabilised in 90% methanol. Cells were stained with Alexa 647-labeled anti-human IFN-γ in
results

Monocytes and \( \Phi \)1 produce IL-23, but not IL-12, in response to various TLR agonists.

LPS is known to induce IL-23, but not IL-12, production in \( \Phi \)1 (5). To determine whether various TLR agonists are capable of inducing IL-23 or IL-12 production in monocytes and \( \Phi \)1, we first tested these capacities in freshly isolated human monocytes. Unstimulated monocytes did not produce IL-23, whereas Zymosan A (agonist for TLR2/6) induced minimal IL-23 production, LPS (TLR4) and CL075 (TLR8/7) each induced small amounts of IL-23, while LPS and CL075 synergized in the induction of IL-23 production in monocytes (Fig. 1A). IL-23 production was also observed in response to LPS plus flagellin (TLR5) but the amount released was similar to that induced by LPS alone. Of note, the amounts of IL-23 produced by \( \text{CD}^{+} \) monocytes varied somewhat between different donors, the relative amount released upon the various TLR stimulations was however similar (data not shown). In none of the supernatants IL-12p70 was detected, given a detection limit of the IL-12p70 ELISA of 3 pg/ml (data not shown).

Next, we compared the amount of IL-23 and IL-12 produced by monocytes to those by cultured \( \Phi \)1. Upon incubation with each of the TLR agonists \( \Phi \)1 produced IL-23 (Fig. 1B). LPS synergized with both CL075 and flagellin in the induction of IL-23. As compared with freshly isolated monocytes at identical cell number and incubation conditions, \( \Phi \)1 produced markedly more IL-23 in response to the TLR agonists. Again, no IL-12p70 production was detected in response to any of the stimuli (data not shown). To verify that the \( \Phi \)1 used in these experiments are capable of producing IL-12p70 they were stimulated with LPS in combination with IFN-\( \gamma \). Large amounts of IL-12p70 were detected in the supernatants (data not shown).

Infection of \( \Phi \)1 with live Salmonella induces IL-23, but not IL-12, production.

To determine whether not only PAMPs such as the TLR agonists, but also live pathogens induce IL-23 rather than IL-12 production in \( \Phi \)1, we infected cultured \( \Phi \)1 with live Salmonella and assessed cytokine release in the culture supernatants. \( \Phi \)1 exposed to and containing ingested Salmonellae produced IL-23 whereas \( \Phi \)1 left unstimulated did not (Fig. 1C). Of note, Salmonella infected \( \Phi \)1 produced markedly more IL-23 as compared with \( \Phi \)1 stimulated with large amounts of LPS (Fig 1C). Similar to stimulation with TLR agonists, we did not detect any IL-12p70 in the supernatants of infected \( \Phi \)1 (data not shown). Moreover, in a related project, micro-array analysis of \( \Phi \)1 infected with live Salmonella for 1, 2, 4, 8 and 24 hours revealed that infection did not induce

combination with PE-labeled anti-human CD56 and FITC-labeled anti-human CD3 (BD PharMingen).
IL12A (IL-12p35) transcription, whereas IL12B (IL-12p40) and IL23A (IL-23p19) transcription were both upregulated in response to Salmonella (16).

Figure 1. TLR stimuli and Salmonella infection induce IL-23 production in human monocytes and Mφ1.

1 · 10⁵ overnight rested anti-CD14 beads-isolated monocytes (A) or 5 · 10⁴ Mφ1 (B) were stimulated with 100 ng/ml LPS, 200 ng/ml flagellin (flag), 1 µg/ml Pam3CSK4, 100 µg/ml Zymosan A, 1 µg/ml CL075, 1 µg/ml CL087, 100 ng/ml LPS plus 200 ng/ml flagellin, LPS 100 ng/ml plus 1 µg/ml CL075 for 24 hours, or left unstimulated. (C) Mφ1 were infected with live Salmonella with a multiplicity of infection (MOI) of 10, left uninfected or were stimulated with 100 ng/ml LPS. Supernatants were collected after 24 hours and IL-23 protein production was assessed by ELISA. Data are means ± standard deviation (SD) of triplicates in one representative experiment of five (A and B) or means of duplicates in one representative experiment of three (C).

TLR stimuli and infection with live Salmonella induce IL-18 and IL-1β production.

We have shown previously that for IL-23 to induce IFN-γ production in NK-like T cells, an additional stimulus such as IL-18 is required (8). Similar to IL-18, IL-1β can costimulate for IFN-γ production (17,18). To determine whether the production of IL-23 occurs in concert with that of IL-18 or IL-1β,
we assayed the production of these cytokines by Mφ1 in response to LPS or infection with *Salmonella*. Unstimulated cells produced minimal IL-18, but no IL-1β. Although IL-18 and IL-1β production in response to LPS and infection varied markedly between donors; Mφ1 of all donors produced both IL-18 and IL-1β in response to these stimulations (Fig. 2A and B). *Salmonella*-infected Mφ1 produced markedly more IL-18 and IL-1β as compared with cells stimulated with LPS (Fig. 2A and B).

Figure 2. *Salmonella* infection induces IL-18 and IL-1β production in Mφ1. 3.3 · 10^5 Mφ1 of five different donors were left unstimulated, stimulated with LPS or infected with *Salmonella* with a MOI of 10. Supernatants were collected after 24 hours and IL-18 (A) and IL-1β (B) production was measured by ELISA. Each dot represents one donor. The mean is indicated by a horizontal line. A paired two-tailed student’s t-test was used for statistical analysis. n.d. = not detected.

**IL-23 and IL-1β synergize in the induction of IFN-γ in CD56+ cells.**

Infection of Mφ1 with live Salmonella resulted in the production of IL-23, IL-18 and IL-1β. IL-23 is reported to induce IFN-γ production in NK, NK-like T cells and in T cells, in synergy with IL-18 (7,8,19). As mentioned before, IL-1β is known to enhance IL-12 induced IFN-γ production (17,18). Therefore, we tested whether perhaps IL-23 in combination with IL-1β could also induce IFN-γ production in CD56+ (NK and NK-like T) cells. Each cytokine alone was not able to induce IFN-γ production (Fig. 3). However, when IL-23 and IL-1β were combined, they synergized in inducing IFN-γ production (Fig. 3). Isolated CD56+ cells consist of CD56+/CD3- NK cells and CD56+/CD3+ NK-like T cells. We next determined which of these two populations were responsible for the observed IFN-γ production by IL-23 plus IL-1β stimulated CD56+ cells. Because sorting CD3+ cells with an anti-CD3 antibody induces undesired activation of the cells, we used intracellular staining for IFN-γ in combination with CD3/CD56 labeling. We arbitrarily designated a population positive for IFN-γ when more than 1% of the cells stained IFN-γ positive. CD56+ cells obtained from eight donors were stimulated with IL-23, IL-1β, IL-18, IL-23 plus IL-1β, IL-23 plus IL-18, or left unstimulated for 48 hours. No significant IFN-γ production was observed in unstimulated cells or cells stimulated with either IL-23, IL-1β or IL-18 (Fig 4). Surprisingly, the cells producing IFN-γ in response to IL-23 plus IL-1β or IL-23 plus IL-18 varied between donors. In response to IL-23 plus IL-1β in half of the donors...
IL-23 positive feedback loop

IFN-γ production was observed in both CD56+/CD3− NK cells and CD56+/CD3+ NK-like T cells, whereas in the other half IFN-γ production was only observed in CD56+/CD3− NK-like T cells (Table 1). In response to IL-23 plus IL-18 IFN-γ production was observed in both populations in seven donors, while in one donor only CD56+CD3− cells produced IFN-γ (Table 1). On average, significant IFN-γ production was observed in response to IL-23 plus IL-1β or IL-18 in NK cells, while in NK-like T cells only IL-23 plus IL-1β resulted in significant IFN-γ production (Fig 4).

Since IL-23 in combination with IL-1β is known to promote the production of IL-17 in memory T cells (20), we also analyzed IL-17 production by CD56+ cells in response to IL-23 and IL-1β. However, in none of the supernatants IL-17 was detected (data not shown).

Supernatants of Salmonella infected Mφ1 induce IFN-γ production in primary CD56+ cells.

So far we found that IL-23, IL-18 and IL-1β, but not IL-12p70, are present in supernatants of Salmonella infected Mφ1. We showed that IL-23 can induce IFN-γ production in CD56+ when IL-1β is present. Previously, we have shown that CD56+ cells produce IFN-γ when stimulated with IL-23 plus IL-18, in the absence of IL-12 (8). Based on these data we expected that supernatants from Salmonella infected Mφ1 would be able to induce IFN-γ production in CD56+ cells. Supernatants of Salmonella infected Mφ1 were indeed able to induce IFN-γ production in primary CD56+ cells (Fig. 5A). Neutralization of LPS in these supernatants did not alter their ability to induce IFN-γ production (data not shown).

Since IL-18 is induced in small amounts only, even after infection by Salmonella, we determined whether IL-18 was a limiting factor in the induction of IFN-γ in CD56+ cells by supernatants of Mφ1 infected with Salmonella. The addition of recombinant IL-18 to the supernatants increased the IFN-γ production by these CD56+ cells (Fig. 5A).
**IL-23 and IL-1β, but not IL-18, in supernatants are critical for the induction of IFN-γ production in CD56⁺ cells.**

To verify the role of IL-23 in the induction of IFN-γ by supernatants of *Salmonella* infected Mφ1, we neutralized IL-23 using an antibody binding the p40 subunit of IL-23. (Note that although the p40 antibody can also neutralize IL-12, we have shown above that no IL-12 was present in these supernatants). When IL-23 was thus neutralized, IFN-γ production was effectively abrogated (Fig. 5B), even when exogenous IL-18 was added (data not shown).

Similarly, to specify the role of IL-18 and IL-1β in the supernatants of *Salmonella*-infected Mφ1 in the induction of IFN-γ production, we used a specific antibody to neutralize these interleukins. Pilot experiments had confirmed that the IL-18 antibody could neutralize a large amount of IFN-γ.
IL-23, in synergy with IL-18 or IL-1β, induces GM-CSF production in CD56+ NK/NK-like T cells.

IL-18 is known to induce GM-CSF production in NK cells in combination with various cytokines (10). To determine whether IL-18 or IL-1β, combined with IL-23 can induce GM-CSF production in human CD56+ NK/NK-like T cells, these cells were stimulated with IL-18, IL-1β or IL-23 and combinations of these cytokines, or left unstimulated for 24 hours. Unstimulated cells and cells stimulated with IL-23 alone did not produce any GM-CSF (Fig. 6A). In contrast, IL-18 alone induced a small amount of GM-CSF, when high concentrations were used. In combination with IL-23 on the other hand, IL-18 induced considerable amounts of GM-CSF in CD56+ cells (Fig. 6A). CD56+ cells stimulated with high
concentrations of IL-1β produced GM-CSF, whereas cells stimulated with lower concentrations of IL-1β did not. IL-23 synergized with IL-1β in inducing GM-CSF (Fig 6B). For both IL-18 and IL-1β, strongest synergy was observed at highest concentrations.

**Figure 6.** IL-23 in synergy with IL-18 or IL-1β induces GM-CSF in CD56⁺ cells. 1·10⁵ anti-CD56 beads isolated cells were rested for 24 hours and then left unstimulated or stimulated with indicated concentrations of IL-23 in combination with various concentrations of IL-18 (A) or IL-1β (B). IL-18 or a combination of these cytokines. Supernatants were collected 24 hours after stimulation and GM-CSF protein production was measured by ELISA. One representative experiment of three is shown.

**GM-CSF and IFN-γ prime monocytes for enhanced IL-23 production.**

Mo1 generated by culturing CD14⁺ monocytes for six days in the presence of GM-CSF are strong producers of IL-23 compared with freshly isolated CD14⁺ monocytes (5) and above. To investigate whether GM-CSF or IFN-γ (known to enhance the expression of the IL-23 subunit IL-12p40 (21)) could prime monocytes directly for enhanced IL-23 production in response to stimulation with heat killed *Salmonella*, we pre-stimulated CD14⁺ cells for 16 hours with GM-CSF or IFN-γ and assessed IL-23 production. Stimulation of monocytes with GM-CSF or IFN-γ alone did not induce IL-23 production (Fig. 7A and 7B). However, sixteen hours of pre-stimulation of monocytes with as little as 50 pg/ml GM-CSF enhanced IL-23 production in response to heat killed *Salmonella* (Fig. 7A), with a dose dependent priming effect (Fig. 7A). Similar to GM-CSF, pre-stimulation of monocytes with IFN-γ also enhanced IL-23 production in response to heat killed *Salmonella*, again in a dose dependent manner (Fig. 7B).
**Table 1** Percentages of IFN-γ producing CD56⁺ cells after stimulation with cytokines.

| Donor | Fraction | IL-23 | IL-1β | IL-18 | IL-23 | IL-1β | IL-18 |
|-------|----------|-------|-------|-------|-------|-------|-------|
| 1     | CD3⁻     | 0,2   | 0,8   | 0,2   | 0,4   | 3,0   | 6,7   |
|       | CD3⁺     | 0,0   | 0,1   | 0,0   | 0,1   | 0,2   | 0,7   |
| 2     | CD3⁻     | 0,1   | 0,3   | 0,2   | 0,3   | 1,9   | 4,4   |
|       | CD3⁺     | 0,1   | 0,1   | 0,1   | 0,2   | 0,6   | 4,8   |
| 3     | CD3⁻     | 0,1   | 0,1   | 0,0   | 0,2   | 1,5   | 7,5   |
|       | CD3⁺     | 0,1   | 1,2   | 0,0   | 0,1   | 11,6  | 35,9  |
| 4     | CD3⁻     | 0,1   | 0,3   | 0,0   | 0,1   | 3,2   | 53,4  |
|       | CD3⁺     | 0,0   | 0,4   | 0,0   | 0,0   | 1,2   | 84,1  |
| 5     | CD3⁻     | 0,2   | 6,1   | 3,9   | 2,8   | 9,7   | 15,8  |
|       | CD3⁺     | 0,1   | 0,6   | 3,9   | 0,3   | 2,3   | 19,5  |
| 6     | CD3⁻     | 0,0   | 0,1   | 0,1   | 0,1   | 1,2   | 3,4   |
|       | CD3⁺     | 0,1   | 0,0   | 0,0   | 0,0   | 0,5   | 10,0  |
| 7     | CD3⁻     | 0,1   | 0,1   | 0,2   | 0,5   | 2,4   | 9,0   |
|       | CD3⁺     | 0,1   | 0,2   | 0,0   | 0,1   | 1,0   | 7,5   |
| 8     | CD3⁻     | 0,1   | 0,3   | 0,0   | 1,0   | 4,7   | 17,8  |
|       | CD3⁺     | 0,0   | 0,0   | 0,0   | 0,0   | 0,1   | 2,7   |

Percentages of IFN-γ producing CD56⁺/CD3⁻ NK cells and CD56⁺/CD3⁺ NK-like T cells for each of eight donors after stimulation of CD56⁺ cells with the indicated cytokines for 48h.

**IL-23 plus IL-1β stimulated CD56⁺ cells prime monocytes for IL-12p70 production.**

To produce IL-12p70 in response to LPS, IFN-γ is needed as an extra stimulus. CD56⁺ cells produce IFN-γ in response to IL-23 plus IL-1β, therefore we wanted to know whether supernatants of IL-23/IL-1β stimulated CD56⁺ cells could prime monocytes for IL-12p70 production in response to LPS. Monocytes were stimulated with LPS, plus or minus supernatants of IL23/IL-1β stimulated CD56⁺ cells or, as a positive control, IFN-γ. Monocytes stimulated with LPS alone did not produce IL-12p70, whereas cells stimulated with LPS in combination with IFN-γ or supernatants of IL-23 plus IL-1β stimulated CD56⁺ cells both produced IL-12p70 (Fig. 8A). To assess the role of IFN-γ present in the supernatants of IL-23 plus IL-1β stimulated CD56⁺ cells in the priming effect on IL-12p70 production by monocytes, we used an IFN-γ neutralizing antibody. Neutralization of IFN-γ greatly diminished the priming effect of these supernatants on LPS induced IL-12p70 production by monocytes (Fig. 8B). Of note, IL-23 plus IL-1β did not directly prime monocytes to produce IL-12p70 in response to LPS (data not shown).
Figure 7. GM-CSF and IFN-γ prime monocytes for enhanced IL-23 production. 1·10^5 CD14+ monocytes were prestimulated with GM-CSF (A) or IFN-γ (B) for 16 hours in concentrations indicated. Subsequently cells were stimulated with heat killed Salmonella (moi=10) or left unstimulated for 24 hours. Supernatants were taken and IL-23 production was measured by ELISA. Data are means ± SD of triplicates in one representative experiment of five.

Figure 8. IFN-γ in supernatants of IL-23 plus IL-1β stimulated CD56+ cells primes monocytes for IL-12p70 production in response to LPS. 1·10^5 CD14+ monocytes were stimulated with 100 ng/ml LPS in combination with 2.5 ng/ml IFN-γ, supernatants of unstimulated CD56+ cells, supernatants of IL-23 plus IL-1β stimulated CD56+ cells, or medium alone for 24 hours (A). 1·10^5 CD14+ monocytes were stimulated with 100 ng/ml LPS in combination supernatants of IL-23 plus IL-1β stimulated CD56+ cells, plus or minus 2 μg/ml anti-IFN-γ for 24 hours (B). Supernatants were taken and IL-12p70 production was measured by ELISA. Data are means ± SD of triplicates from one representative experiment of three.
In this study we demonstrate that human monocytes and cultured pro-inflammatory macrophages (i.e., Mφ1) both produce IL-23, IL-18 and IL-1β in response to various TLR agonists, during co-incubation and upon ingestion of live *Salmonella*. Subsequently, in response to IL-23 in combination with IL-18 or IL-1β, CD56⁺ cells produce IFN-γ and GM-CSF. These cytokines in turn enhance IL-23 production by monocytes and macrophages in response to TLR agonists, implying a positive feedback loop. Furthermore, supernatants of *Salmonella* infected Mφ1 induce IFN-γ production in CD56⁺ cells and this induction of IFN-γ was critically dependent on IL-23 and IL-1β. Finally, supernatants from IL-23 plus IL-1β stimulated CD56⁺ cells allowed monocytes to produce IL-12p70 in response to LPS.

The assumption of an IL-23 positive feedback loop is based on the following observations: (1) We demonstrated that monocytes as well as Mφ1 are able to produce IL-23 in response to various TLR agonists. In addition, monocytes and Mφ1 produced small amounts of IL-18 and IL-1β in response to individual TLR agonists, while cells infected with live *Salmonella* produced large amounts of IL-18, IL-1β and IL-23. In line, Verreck *et al.* showed that Mφ1 produce IL-23 and IL-1β in response to LPS or mycobacterial sonicate (22). (2) Guia *et al.* reported that in the presence of macrophages infected with *Salmonella* in vitro, CD56⁺ NK-like T cells, but not CD56⁻ T cells produce IFN-γ in absence of TCR stimulation (23). Here we show that IL-23 and IL-1β in these supernatants of *Salmonella* infected Mφ1 were critical components for the induction of IFN-γ production in the CD56⁺ NK/NK-like T cells, because neutralization of these interleukins resulted in abrogation or a strong reduction of IFN-γ production, respectively. (3) Recombinant IL-18 was able to enhance the induction of IFN-γ in CD56⁺ in response to supernatants of *Salmonella* infected Mφ1. However, neutralization of IL-18 did not significantly reduce the IFN-γ production. These results support that IL-23 and IL-1β, but not IL-18, in the supernatant of *Salmonella* infected Mφ1 are critical for the induction of IFN-γ in CD56⁺ cells. Moreover, in CD56⁺ cells stimulated with IL-23 no synergy is seen with IL-18 when concentrations lower than 20 ng/ml IL-18 are used (8), indicating that the IL-18 concentration induced by *Salmonella* (which was ~1-4 ng/ml) may be too low to synergize with IL-23 in inducing IFN-γ. In addition, *Salmonella* infection is known to induce TNF production in macrophages and TNF has been reported to enhance IFN-γ production (18,24). Therefore, in our experiments, TNF in the supernatants of infected Mφ1 may also enhance IFN-γ production. However, we did not determine the role of TNF in this respect. (4) IFN-γ and GM-CSF both enhanced IL-23 production in monocytes in response to various stimulations. (5) Moreover, both cytokines could be induced by IL-23, in combination with IL-18 or IL-1β, in CD56⁺ cells. Depending on the concentrations used, IL-23 plus
IL-18 or IL-1β induced more than 200 pg/ml GM-CSF, a concentration which we have shown to be sufficient to prime CD14\(^+\) monocytes for enhanced IL-23 production.

Together these observations confirm the presence of a positive feedback loop in which IL-23 can enhance its own expression via the induction of IFN-γ and GM-CSF. In line with our observations, IFN-γ was recently reported to enhance Francisella tularensis induced IL-23 in human monocytes (25). IFN-γ allows for the transcription of IL-12p35 in response to LPS (26) and for the induction of IL-12 in response to a PAMP an additional stimulus such as IFN-γ is needed (5). Herein we show that IL-23 together with IL-1β present in supernatants of Salmonella infected Mϕ1 can provide this costimulus by the induction of IFN-γ in NK-like T cells, thereby allowing subsequent IL-12p70 production in response to Salmonella and the initiation of a Th1 response. In contrast, in human DCs IFN-γ can inhibit IL-23p19 mRNA transcription (27), emphasizing the complexity of the regulation of this cytokine.

In this study we report on a positive feedback of IL-23 production, but negative feedback mechanisms may exist as well. For instance, IL-4 and IL-10 are both reported to inhibit the induction of IL-23 and may serve as a negative feedback (28). IL-4 may be important in balancing IL-23 and IL-12 production as IL-4 can enhance IL-12p70 production (29-31). It would be interesting to explore the effects of these and other potential negative regulators of IL-23.

To reach the conclusion on a positive feedback loop in which IL-23 enhances its own expression via the induction of IFN-γ and GM-CSF, the following pitfalls of this study need to be considered. Firstly, in supernatants of Mϕ1 infected with live Salmonella, we neutralized IL-23 using an antibody which is able to neutralize IL-12p70 as well. Though we did not detect IL-12p70 and IL-12p35 mRNA expression was not induced by infection with Salmonella, one should bear in mind that the detection limit of the IL-12p70 ELISA used was 3 pg/ml and that we can not exclude that the effect observed after neutralizing the IL-23 is due to the neutralization of small, undetectable amounts of IL-12p70. Secondly, the concentrations of the TLR agonists used may exceed physiological relevant conditions. For example, the concentrations of Salmonella LPS added to the cells used in this study are likely to differ from LPS concentration when Mϕ1 are being infected with live Salmonella. During sepsis 5-10 pg/ml LPS can be detected in the blood (32). Thirdly, between donors we observed interindividual differences in cytokine production in response to the stimulations used. This may reflect differences in responsiveness to stimulation and differences in capacity to produce cytokines between cells obtained from different donors. We observed for example remarkable interindividual differences in the subset of IFN-γ producing CD56\(^+\) cells in response to IL-23 in combination with IL-1β or IL-18.

In addition to the elucidation of the positive feed-back loop of IL-23 expression we observed a synergy between LPS (TLR4) and flagellin (TLR5) and between LPS and CL075 (TLR8/7) with respect to the induction of IL-23 production in monocytes and Mϕ1. During an infection, synergy
between TLRs is likely of importance because pathogens express multiple TLR agonists. LPS and flagellin for instance, which in synergy induce large quantities of IL-23 in Mφ1, are both expressed by *Salmonella*. Synergy between LPS (TLR4) and R848, another TLR8/7 agonist, has been observed in the induction of IL-12 and IL-23 in human DCs (33). Both TLR8 and TLR4 are implicated in the resistance against *M. tuberculosis* (34,35), suggesting the synergy we observed between the TLR4 and the TLR8/7 agonists may be relevant in mycobacterial infections.

In conclusion, we have shown that various TLR agonists and infection with *Salmonella* can induce IL-23, IL-18 and IL-1β, but not IL-12, production in monocytes and Mφ1. Furthermore, our findings indicate that a positive feedback loop exists in which IL-23 can enhance its own production via the induction of IFN-γ and GM-CSF, which both prime monocytes for enhanced IL-23 production. Last, IL-23, in combination with IL-1β, could prime monocytes to produce IL-12p70 in response to LPS, via the activation of CD56⁺ cells, thereby amplifying the type-1 cytokine pathway to IFN-γ production.

IL-23 plus IL1β induced IFN-γ production in CD56⁺ cells, which consist of CD56⁺/CD3⁻ NK cells and CD56⁺CD3⁺ NK-like T cells. In half of the donors IFN-γ production was observed in both NK cells and NK-like T cells, whereas in the other half IFN-γ production was observed only in the NK cells. Possible explanations for these interindividual differences may be previous (recent) exposure to different pathogens or genetic differences between donors; these may be elucidated when individual donors are assayed at regular intervals over a longer time period to determine whether or not the individual cytokine production profiles are constant.
References

1. van de Vosse, E., and T. H. Ottenhoff. 2006. Human host genetic factors in mycobacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunity. Microbes. Infect. 8: 1167-1173.

2. Abdi, K., N. Singh, and P. Matzinger. 2006. T-cell control of IL-12p75 production. Scand. J. Immunol. 64: 83-92.

3. Feinberg, J., C. Fieschi, R. Doffinger, M. Feinberg, T. Leclerc, S. Boisson-Dupuis, C. Picard, J. Bustamante, A. Chapgier, O. Filipe-Santos, C. L. Ku, L. de Beaucoudrey, J. Reichenbach, G. Antoni, R. Balde, A. Alcais, and J. L. Casanova. 2004. Bacillus Calmette Guerin triggers the IL-12/IFN-gamma axis by an IRAK-4- and NEMO-dependent, non-cognate interaction between monocytes, NK, and T lymphocytes. Eur. J. Immunol. 34: 3276-3284.

4. Happel, K. I., P. J. Dubin, M. Zheng, N. Ghiardi, C. Lockhart, L. J. Quinton, A. R. Odden, J. E. Shellito, G. J. Bagby, S. Nelson, and J. K. Kolls. 2005. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J. Exp. Med. 202: 761-769.

5. Verreke, F. A., T. de Boer, D. M. Langenberg, M. A. Hoeve, M. Kramer, E. Vaisberg, R. Kastelein, A. Kolk, R. de Waal-Malefyt, and T. H. Ottenhoff. 2004. Human IL-23-producing type 1 macrophages promote but inhibit IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl. Acad. Sci. U. S. A. 101: 4560-4565.

6. Hayes, M. P., J. Wang, and M. A. Norcross. 1995. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 86: 646-650.

7. Oppmann, B., R. Lesley, B. Blom, J. C. Timans, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, F. Zonin, E. Vaisberg, T. Churakova, M. Liu, D. Gorman, J. Wagner, S. Zuarawski, Y. Liu, J. S. Abrams, K. W. Moore, D. Rennick, R. de Waal-Malefyt, C. Hannum, J. F. Bazan, and R. A. Kastelein. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 13: 715-725.

8. van de Wetering, D., R. A. de Paus, J. T. Van Dissel, and E. van de Vosse. 2009. IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NK-like T cell function differentially from IL-12. Int. Immunol. 21: 145-153.

9. Hunter, C. A., J. Timans, P. Pisacane, S. Menon, G. Cai, W. Walker, M. Aste-Amezaga, R. Chizzonite, J. F. Bazan, and R. A. Kastelein. 1997. Comparison of the effects of interleukin-1 alpha, interleukin-1 beta and interferon-gamma-inducing factor on the production of interferon-gamma by natural killer. Eur. J. Immunol. 27: 2787-2792.

10. Fehniger, T. A., M. H. Shah, M. J. Turner, J. B. VanDeusen, S. P. Whitman, M. A. Cooper, K. Suzuki, M. Wechsler, F. Goosaid, and M. A. Caligiuri. 1999. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol. 162: 4511-4520.

11. Bermudez, L. E., C. A. Kemper, and S. C. Deresinski. 1994. Dysfunctional monocytes from a patient with disseminated Mycobacterium kansasii infection are activated in vitro and in vivo by GM-CSF. Biotherapy 8: 135-142.

12. Suzuki, K., W. J. Lee, T. Hashimoto, E. Tanaka, T. Murayama, R. Amitani, K. Yamamoto, and F. Kuze. 1994. Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumour necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex. Clin. Exp. Immunol. 98: 169-173.

13. Carryn, S., S. Van de Velde, F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2004. Impairment of growth of Listeria monocytogenes in TH-1 macrophages by granulocyte macrophage colony-stimulating factor: release of tumor necrosis factor-alpha and nitric oxide. J. Infect. Dis. 189: 2101-2109.

14. Wing, E. J., D. M. Magee, T. L. Whiteside, S. S. Kaplan, and R. K. Shadduck. 1989. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood 73: 643-646.

15. Burchett, S. K., W. M. Weaver, J. A. Westall, A. Larsen, S. Kronheim, and C. B. Wilson. 1988. Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J. Immunol. 140: 3473-3481.

16. van de Wetering, D., R. A. de Paus, J. T. Van Dissel, and E. van de Vosse. 2009. Salmonella Induced IL-23 and IL-1beta Allow for IL-12 Production by Monocytes and Mø1 through Induction of IFN-gamma in CD56 NK/NK-Like T Cells. PLoS. One. 4: e8396.

17. Tominaga, K., T. Yoshimoto, K. Torigoe, M. Kurimoto, K. Matsui, T. Hada, H. Okamura, and K. Nakanishi. 2000. IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. Int. Immunol. 12: 151-160.
18. Cooper, M. A., T. A. Fehniger, A. Ponnappan, V. Mehta, M. D. Wewers, and M. A. Caligiuri. 2001. Interleukin-1beta costimulates interferon-gamma production by human natural killer cells. *Eur. J. Immunol.* 31: 792-801.

19. Butcher, J. P., M. V. Rajaram, L. P. Ganesan, K. V. Parsa, C. D. Clay, L. S. Schlesinger, and S. Trandapagni. 2007. Francisella tularensis induces IL-23 production in human monocytes. *J. Immunol.* 178: 4445-4454.

20. van Beelen, A. J., Z. Zelinkova, E. W. Taanman-Kueter, F. J. Muller, D. W. Hommes, S. A. Zaat, M. L. Kapseen, and E. C. de Jong. 2007. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. *Immunity.* 27: 660-669.

21. Ma, X., J. M. Chow, G. Gri, G. Carra, F. Gerosa, S. F. Wolf, R. Dzialo, and G. Trinchieri. 1996. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocyte cells. *J. Exp. Med.* 183: 147-157.

22. Verreck, F. A., T. de Boer, D. M. Langenberg, L. van der Zanden, and T. H. Ottenhoff. 2006. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. *J. Leukoc. Biol.* 79: 285-293.

23. Guia, S., C. Cognet, de Beaucoudrey L., M. S. Tessmer, E. Jouanguy, C. Berger, O. Filipe-Santos, J. Feinberg, Y. Camcioglu, J. Levy, S. Al Jumaah, S. Al-Hajjar, J. L. Stephan, C. Fieschi, L. Abel, L. Brossay, J. L. Casanova, and E. Vivier. 2008. A role for interleukin-12/23 in the maturation of human natural killer and CD56+ T cells in vivo. *Blood* 111: 5008-5016.

24. Tripp, C. S., S. F. Wolf, and E. R. Unanue. 1993. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. *Proc. Natl. Acad. Sci. U. S. A* 90: 3725-3729.

25. Butcher, J. P., K. V. Parsa, C. B. Marsh, and S. Trandapagni. 2008. IFN-gamma enhances IL-23 production during Francisella infection of human monocytes. *FEBS Lett.* 582: 1044-1048.

26. Hayes, M. P., F. J. Murphy, and P. R. Burd. 1998. Interferon-gamma-dependent inducible expression of the human interleukin-12 p35 gene in monocytes initiates from a TATA-containing promoter distinct from the CpG-rich promoter active in Epstein-Barr virus-transformed lymphoblastoid cells. *Blood* 91: 4646-4651.

27. Gerosa, F., B. Baldani-Guerra, L. A. Lyakh, G. Batoni, S. Esin, R. T. Winkler-Pickett, M. R. Consolaro, M. De Marchi, D. Giachino, A. Robbiano, M. Astegiano, A. Sambataro, R. A. Kastelein, G. Carra, and G. Trinchieri. 2008. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. *J. Exp. Med.* 205: 1447-1461.

28. Pithoron, J., S. Matikainen, and I. Julkunen. 2002. Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. *J. Immunol.* 169: 5673-5678.

29. Hochrein, H., M. O’Keeffe, T. Luft, S. Vandenabeele, R. J. Grumont, E. Maraskovsky, and K. Shortman. 2000. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. *J. Exp. Med.* 192: 823-833.

30. D’Andrea, A., X. Ma, M. Aste-Amezaga, C. Paganin, and G. Trinchieri. 1995. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. *J. Exp. Med.* 181: 537-546.

31. Marshall, J. D., S. E. Robertson, G. Trinchieri, and J. Chehimi. 1997. Priming with IL-4 and IL-13 during HIV-1 infection restores in vitro IL-12 production by mononuclear cells of HIV-infected patients. *J. Immunol.* 159: 5705-5714.

32. Bouten, H., E. F. Schippers, S. A. Luelmo, M. I. Versteegh, P. Ros, H. F. Guiot, M. Frolich, and J. T. Van Dissel. 2002. No effect of preoperative selective gut decontamination on endotoxemia and cytokine activation during cardiopulmonary bypass: a randomized, placebo-controlled study. *Crit Care Med.* 30: 38-43.

33. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. *Nat. Immunol.* 6: 769-776.

34. Jo, E. K., C. S. Yang, C. H. Choi, and C. V. Harding. 2007. Intracellular signalling cascades regulating innate immune responses to Mycobacteria: branching out from Toll-like receptors. *Cell Microbiol.* 9: 1087-1098.

35. Davila, S., M. L. Hibberd, D. R. Hari, H. E. Wong, E. Sahiratmadja, C. Bonnard, B. Alisjahbana, J. S. Szeszko, Y. Balabanova, F. Drobniowski, R. van Crevel, E. van de Vosse, S. Neijentsev, T. H. Ottenhoff, and M. Seielstad. 2008. Genetic association and expression studies indicate a role of Toll-like receptor 8 in pulmonary tuberculosis. *PLoS. Genet.* 4: e1000218.
